Immune Checkpoint Inhibition with Ifowonco’s LAG-3 Inhibitors
Ifowonco Informatics Inc. has developed a groundbreaking class of therapeutic assets: novel small molecule Lymphocyte Activation Gene-3 (LAG-3) inhibitors, representing a key cornerstone of our intellectual property portfolio and a significant potential advancement in cancer immunotherapy. These assets are patented and their development, and characterization have also been detailed in our recent publication.
LAG-3, also known as CD223, is a critical immune checkpoint protein that acts as a negative regulator of T-cell proliferation and activation. While essential for preventing excessive immune responses, many cancers exploit LAG-3 to suppress the body’s natural anti-tumor immunity, allowing them to evade detection and elimination. By inhibiting LAG-3, we can restore vital immune function and enhance the body’s ability to fight cancer. As a clinically significant immune checkpoint, LAG-3 inhibition offers immense therapeutic potential, particularly in combination with other immunotherapies targeting PD-1 and CTLA-4.
The Ifowonco Advantage: Semi-Allosteric Small Molecule Design
Unlike existing antibody-based therapies, such as the FDA-approved relatlimab, Ifowonco’s LAG-3 inhibitors are small molecules designed with a novel semi-allosteric mechanism of action. This dual-mechanism is hypothesized to induce a durable conformational shift, potentially keeping LAG-3 in an inactive state even after the inhibitory compound dissociates, offering sustained therapeutic benefits.
Superior Efficacy and Patient-Friendly Profile
Ifowonco’s small molecule LAG-3 inhibitors offer compelling advantages over traditional antibody therapies:
- High Potency: Our lead compounds, such as LG-306 (24 nM) and LG-310 (62 nM), demonstrate deep-nanomolar potency in vitro.
- Superior Cellular Activity: In rigorous cell-based assays mimicking the immune response, LG-310 notably outperformed commercial anti-LAG-3 antibodies, including relatlimab, at saturating doses. This superior maximal efficacy is attributed directly to our innovative semi-allosteric mechanism.
- Oral Bioavailability and Tunable Pharmacokinetics: Being small molecules, our inhibitors offer the potential for oral administration, along with flexible pharmacokinetics and enhanced tissue penetration—attributes that large monoclonal antibodies typically lack.
- Reduced Immunogenicity: Our compounds are also less likely to provoke an immune response compared to antibody-based treatments, leading to a more favorable safety profile.
A Cornerstone of Our Portfolio and Future Vision
The development of these patented semi-allosteric small molecule LAG-3 inhibitors underscores Ifowonco’s commitment to pioneering next-generation therapeutics. This collection of assets represents a key part of our portfolio, offering a more flexible and patient-friendly therapeutic profile in oncology and other immune-related disorders. We are advancing these compounds with further optimization and testing in humanized animal models to realize their full potential in vivo. For more information and for potential licensing opportunities please contact [email protected]